Accelerated or Hyperfractionated Radiotherapy for Esophageal Carcinoma: a Meta-analysis of Randomized Controlled Trials

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2017 Jun 28

PMID 28652779

Citations 2

Authors

Yingyu Liu

Changgui Kou

Yingying Su

Yangyu Zhang

Yueyue You

Lili Zhang

Mohan Wang

Yingli Fu

Xiaojun Ren

Yanming Yang

Affiliations

Soon will be listed here.

Abstract

Objective: The goal of this study was to evaluate the efficacy and safety of modified (accelerated and/or hyperfractionated) radiotherapy in the treatment of esophageal carcinoma, compared with conventional radiotherapy.

Methods: Studies published in the PubMed, Cochrane Library, EMBASE, CBM, VIP, CNKI and Wanfang databases in the most recent two decades were searched for use in this meta-analysis. Only randomized controlled trials were included. The heterogeneity analysis and calculation of the pooled odds ratio (OR) were performed using RevMan 5.3 software. The assessment of publication bias and sensitivity analyses was conducted using Stata 13.0 software.

Results: Twenty trials with a total of 1,742 Chinese patients who met the inclusion criteria were included. The pooled results showed that modified radiotherapy improved the response rate compared with conventional schedules (OR =3.90, 95% confidence interval [CI]: 2.47-6.16, <0.001). Favorable results were observed for the 1-year (OR =2.58, 95% CI: 2.05-3.26, <0.001), 3-year (OR =2.30, 95% CI: 1.83-2.89, <0.001) and 5-year (OR =2.36, 95% CI: 1.74-3.21, <0.001) overall survival and for the 1-year (OR =2.46, 95% CI: 1.72-3.51, <0.001), 3-year (OR =2.08, 95% CI: 1.49-2.90, <0.001) and 5-year (OR =2.15, 95% CI: 1.38-3.34, <0.001) overall local control rate in the modified fractionation radiotherapy group. However, the altered radiotherapy increased the risk of acute radiation esophagitis (OR =1.70, 95% CI: 1.27-2.28, <0.001) and acute radiation tracheitis (OR =1.47, 95% CI: 1.09-1.99, =0.01). No significant differences in the risk of esophageal perforation (OR =1.30, 95% CI: 0.51-3.32, =0.58) or esophagorrhagia (OR =0.88, 95% CI: 0.41-1.88, =0.74) were found between the two groups.

Conclusion: Chinese patients with squamous cell esophagus carcinomas gained a significant benefit in terms of the response rate, survival and local control rates from the modified fractionation radiotherapy, but also had an increased risk of acute radiation reactions. Otherwise, there was no observed statistically significant difference in terms of early adverse reactions.

Citing Articles

Current and future on definitive concurrent chemoradiotherapy for inoperable locally advanced esophageal squamous cell carcinoma.

Xie R, Cai Q, Chen T, Huang H, Chen C Front Oncol. 2024; 14:1303068.

PMID: 38344202 PMC: 10853813. DOI: 10.3389/fonc.2024.1303068.

Accelerated Hyperfractionated Radiotherapy versus Conventional Fractionation Radiotherapy for Head and Neck Cancer: A Meta-Analysis of Randomized Controlled Trials.

Zhu B, Kou C, Bai W, Yu W, Zhang L, Yu X J Oncol. 2019; 2019:7634746.

PMID: 31885584 PMC: 6914880. DOI: 10.1155/2019/7634746.

References

Tran G, Sun X, Abnet C, Fan J, Dawsey S, Dong Z . Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer. 2004; 113(3):456-63. DOI: 10.1002/ijc.20616. View

Yamada S, Takai Y, Nemoto K, Ogawa Y, Kakuto Y, Hoshi A . Low-dose rate telecobalt therapy as a boost against esophageal carcinomas. Cancer. 1992; 69(5):1099-103. DOI: 10.1002/cncr.2820690505. View

Sun S, Liu Y, Ye T, Zhang W, Shen W, Shi J . Randomized clinical trial on seven-day-per-week continuous accelerated irradiation for patients with esophageal carcinoma: preliminary report on tumor response and acute toxicity. World J Gastroenterol. 2006; 12(43):7047-50. PMC: 4087353. DOI: 10.3748/wjg.v12.i43.7047. View

Struikmans H, Kal H, Hordijk G, van der Tweel I . Proliferative capacity in head and neck cancer. Head Neck. 2001; 23(6):484-91. DOI: 10.1002/hed.1064. View

Peters , Ang . The Role of Altered Fractionation in Head and Neck Cancers. Semin Radiat Oncol. 1992; 2(3):180-194. DOI: 10.1053/SRAO00200180. View

Cummings B, Keane T, Pintilie M, Warde P, Waldron J, Payne D . Five year results of a randomized trial comparing hyperfractionated to conventional radiotherapy over four weeks in locally advanced head and neck cancer. Radiother Oncol. 2007; 85(1):7-16. DOI: 10.1016/j.radonc.2007.09.010. View

Peters L, Ang K, Thames Jr H . Accelerated fractionation in the radiation treatment of head and neck cancer. A critical comparison of different strategies. Acta Oncol. 1988; 27(2):185-94. DOI: 10.3109/02841868809090339. View

Skladowski K, Maciejewski B, Golen M, Pilecki B, Przeorek W, Tarnawski R . Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer - report on 3-year tumour control and normal tissue toxicity. Radiother Oncol. 2000; 55(2):101-10. DOI: 10.1016/s0167-8140(00)00139-0. View

Fu K, Pajak T, Trotti A, Jones C, Spencer S, Phillips T . A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG.... Int J Radiat Oncol Biol Phys. 2000; 48(1):7-16. DOI: 10.1016/s0360-3016(00)00663-5. View

10.

Suit H, HOWES A, Hunter N . Dependence of response of a C3H mammary carcinoma to fractionated irradiation on fractionation number and intertreatment interval. Radiat Res. 1977; 72(3):440-54. View

11.

Brenner B, Ilson D, Minsky B . Treatment of localized esophageal cancer. Semin Oncol. 2004; 31(4):554-65. DOI: 10.1053/j.seminoncol.2004.04.015. View

12.

Overgaard J, Sand Hansen H, Specht L, Overgaard M, Grau C, Andersen E . Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet. 2003; 362(9388):933-40. DOI: 10.1016/s0140-6736(03)14361-9. View

13.

Andrici J, Eslick G . Hot Food and Beverage Consumption and the Risk of Esophageal Cancer: A Meta-Analysis. Am J Prev Med. 2015; 49(6):952-60. DOI: 10.1016/j.amepre.2015.07.023. View

14.

Bourhis J, Overgaard J, Audry H, Ang K, Saunders M, Bernier J . Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet. 2006; 368(9538):843-54. DOI: 10.1016/S0140-6736(06)69121-6. View

15.

Arriagada R, Komaki R, Cox J . Radiation dose escalation in non-small cell carcinoma of the lung. Semin Radiat Oncol. 2004; 14(4):287-91. DOI: 10.1016/j.semradonc.2004.07.003. View

16.

Donaldson S, Meza J, Breneman J, Crist W, Laurie F, Qualman S . Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma--a report from the IRSG. Int J Radiat Oncol Biol Phys. 2001; 51(3):718-28. DOI: 10.1016/s0360-3016(01)01709-6. View

17.

EDSMYR F, Andersson L, Esposti P, LITTBRAND B, Nilsson B . Irradiation therapy with multiple small fractions per day in urinary bladder cancer. Radiother Oncol. 1985; 4(3):197-203. DOI: 10.1016/s0167-8140(85)80084-0. View

18.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

19.

Pinto L, Canary P, Araujo C, Bacelar S, Souhami L . Prospective randomized trial comparing hyperfractionated versus conventional radiotherapy in stages III and IV oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys. 1991; 21(3):557-62. DOI: 10.1016/0360-3016(91)90670-y. View

20.

Ahmed K, Correa C, Dilling T, Rao N, Shridhar R, Trotti A . Altered fractionation schedules in radiation treatment: a review. Semin Oncol. 2014; 41(6):730-50. DOI: 10.1053/j.seminoncol.2014.09.012. View